Skip to content

Environmental Pollutants and Neurological Disorders

Environmental Pollutants and Neurological Disorders: Clinical and Mechanistic Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07140601
Acronym
CLEAN
Enrollment
500
Registered
2025-08-24
Start date
2025-08-01
Completion date
2027-08-01
Last updated
2025-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Dementia, Brain Tumours, Cerebrovascular Disorders

Keywords

Environmental Pollutants, Exposomics, Pathogenic Mechanisms, Neurological Disorders, Neurosurgical Patients

Brief summary

Environmental pollutants have emerged as a major global health concern, with growing evidence linking exposure to both traditional contaminants such as heavy metals (lead, mercury, cadmium, arsenic) and novel pollutants-including micro- and nanoplastics, per- and polyfluoroalkyl substances (PFAS), antibiotics, and endocrine-disrupting chemicals-to adverse neurological outcomes. These pollutants can cross or disrupt the blood-brain barrier, accumulate in neural tissue, and trigger oxidative stress, inflammation, epigenetic modifications, and metabolic reprogramming. Brain tumours and cerebrovascular diseases represent two major categories of neurosurgical disorders with high morbidity and mortality. However, their interaction with environmental pollutant exposure remains poorly understood. Recent studies suggest that pollutant-induced molecular alterations, such as aberrant DNA methylation, lipid metabolism disruption, and neurovascular endothelial dysfunction, may contribute to tumour initiation, malignant progression, aneurysm formation, and stroke occurrence. Given the increasing human exposure to these pollutants and the lack of large-scale clinical data, it is urgent to establish a systematic investigation in neurosurgical patients. This study aims to profile pollutant exposure (heavy metals, PFAS, microplastics, and other novel contaminants) using multi-biospecimen analysis (blood, urine, hair, tumour and peri-tumour tissues), and to explore their mechanistic links to the pathogenesis of brain tumours and cerebrovascular diseases. The findings are expected to provide new evidence for understanding environment-brain interactions and to identify potential biomarkers for disease risk stratification and prevention.

Interventions

None listed

Sponsors

Chinese Research Academy of Environmental Sciences
CollaboratorOTHER
Nanjing University
CollaboratorOTHER
Nanjing Institute of Environmental Sciences
CollaboratorUNKNOWN
Chinese Academy of Environmental Planning
CollaboratorUNKNOWN
Peking Union Medical College
CollaboratorOTHER
National Human Brain Bank for Development and Function
CollaboratorUNKNOWN
Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years of age or older; * Able to give informed consent to participate in the research.

Exclusion criteria

* Refusal to participate. * Pregnant or breastfeeding woman.

Design outcomes

Primary

MeasureTime frameDescription
Overall Survival (OS)Until death or study completion (24 months)OS is defined as the time from the sample collection date to death due to any cause. All other participants will be censored at the last date known to be alive.

Secondary

MeasureTime frameDescription
Progression-Free Survival (PFS)Until progression or death or study completion (24 months)PFS is defined as the duration of time from sample collection date to time of progression or death, whichever occurs first.
modified Rankin Scale (mRS)90 days after sample collectionPatients' mRS scores at 90 days after sample collection.

Countries

China

Contacts

Primary ContactRunting Li, MD
tt18080lrt@163.com+86 15753166690

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026